Abstract: A method of training a neural network to approximate a forecasting error of a passenger-demand forecasting model that includes calculating, using the forecasting model, a historical passenger demand forecast for each key level in a set of key levels and for each departure date in a set of historical departures dates; applying a dropout model to the historical passenger demand forecasts to create a training sample; training, using the historical passenger demand forecasts and the training sample, the neural network, to approximate forecasting errors associated with the forecasting model; calculating, using the forecasting model, a future passenger demand forecast for each key level in the set of key levels and for each departure date in a set of future dates; and approximating, using the trained neural network, the forecasting error associated with the future passenger demand forecasts for the second set of departure dates.

Abstract: Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.

Abstract: Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.

Abstract: Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.

Abstract: A computer implemented method for receiving data to a targeted logical partition. A computer locates buffer element in reliance on a connection status bit array. The computer copies control information to the targeted logical partition's local storage. The computer updates a targeted logical partition's local producer cursor based on the control information. The computer copies data to an application receive buffer. The computer determines that an application completes a receive operation. Responsive to a determination that the application completed the receive operation, the computer a targeted logical partition's local consumer cursor to match the targeted logical partition's producer cursor.

Abstract: Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.

Abstract: Experimental autoimmune encephalomyelitis (EAE) is a ThI-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). Herein it is demonstrated that CXCR2, a chemokine receptor involved in the recruitment of neutrophils, is expressed in tissues with EAE lesions. Blockade or deficiency of CXCR2 reduces the infiltration of neutrophils to sites of inflammation. Thus provided herein are reagents that antagonize or inhibit ELR+CXC chemokines and methods of use of these reagents in preventing and treating organ-specific autoimmune diseases like multiple sclerosis, and methods or treating various inflammatory conditions and diseases.

Abstract: Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). In this study it was demonstrate that CXCL13, a chemokine involved in the development of secondary lymphoid tissues, is expressed in CD11c+ myeloid cells that accumulate in EAE lesions. Blockade or deficiency of CXCL13 ameliorates clinical EAE, both during acute and relapsing stages. CXCL13 deficiency did not inhibit the priming or differentiation of autoimmune effector T-cells in the periphery, but appeared to exert its effects during the effector phase of pathogenesis. These findings indicate that reagents that antagonize or inhibit CXCL13 are useful for the treatment of neuroinflammatory diseases such as MS.